Company Overview
Company Type: Private Company
Company Status: Operating Subsidiary
Website: -
Global Number of Employees (Latest): 3,900
Year Founded: 1998
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Patheon Pharmaceuticals Inc., a contract manufacturing organization, develops, manufactures, and supplies pharmaceutical products. Patheon Pharmaceuticals Inc. was formerly known as Aventis Pharmaceuticals Inc., Cincinnati Plant and changed its name to Patheon Pharmaceuticals Inc. in January 2003. The company was incorporated in 1998 and is based in Pittsburgh, Pennsylvania. As of December 31, 2003, Patheon Pharmaceuticals Inc. operates as a subsidiary of Patheon U.S. Holdings Inc.


Financial Information (Currency: CAD, in mm)
Total Revenue
 10.1
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Global Number of Employees (Latest)
 3,900
Net Debt
-
U.S. Number of Employees 2018
 3,900
U.S. Number of Employees 2017
 3,653
U.S. Last Year Employee Growth %
 6.8
* Hover over data point numbers for date and source.

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Life Sciences Tools and Services


Primary Office Location
300 Industry Drive | Pittsburgh, PA | 15275 | United States
Phone: 513 948 9111   Fax: 513 948 7076

Parent Company
Patheon U.S. Holdings Inc.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-16-2002
Dec-31-2002
Merger/Acquisition
Target
Aventis Pharmaceuticals Inc., Cincinnati Plant (nka:Patheon Pharmaceuticals Inc.)
Patheon Inc. (nka:Patheon N.V.)
Sanofi US Services Inc.
29.80
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Dec-05-2022
Client Announcements
AcelRx Pharmaceuticals, Inc. Announces Termination of Manufacturing Services Agreement with Patheon Pharmaceuticals Inc
Jul-26-2022
Client Announcements
Napo Pharmaceuticals, Inc. Enters into Master Manufacturing Services Agreement with Patheon Pharmaceuticals Inc
Jan-24-2022
Client Announcements
Petros Pharmaceuticals, Inc. Enters Technology Transfer Service Agreement with Patheon Pharmaceuticals
May-14-2020
Client Announcements
ChemoCentryx, Inc. Enters into a Product Agreement with Patheon Pharmaceuticals Inc
Aug-23-2017
Client Announcements
AcelRx Pharmaceuticals, Inc. Enters into Second Amendment to the Manufacturing Services Agreement with Patheon Pharmaceuticals Inc


Last 10 Investment Research Documents
No Investment Research returned. This can be caused by entitlement settings or your template settings.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-15-2015
Oct-08-2015
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01, 9.01)
52 KB
Jan-28-2014
Jan-24-2014
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
13 KB
Nov-18-2013
Nov-13-2013
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
14 KB
Sep-26-2013
Sep-25-2013
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
15 KB
Jul-15-2013
Jul-10-2013
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
31 KB
Jan-25-2013
Jan-18-2013
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
17 KB
Dec-17-2012
Dec-14-2012
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01, 2.01, 2.03, 8.01, 9.01)
2 MB
Sep-14-2012
Sep-12-2012
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01, 9.01)
30 KB
Dec-20-2011
Dec-19-2011
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
26 KB
Nov-17-2010
Nov-15-2010
Patheon Pharmaceuticals Inc.
SEC
8-K (1.01)
22 KB

Key Executives and Professionals Details
No Key Executives and Professionals exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
